ReviewJournal of clinical medicine2020
CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis.
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 62 citations in OpenAlex.
- Considerations for the Role and Implementation of Reproductive Health Shared Decision-Making Interventions for Cystic Fibrosis: A Qualitative Investigation of Perspectives From Clinicians and Females With Cystic Fibrosis.Pediatric pulmonology · 2026Article
- Psychosocial Aspects of Cystic Fibrosis: A Mixed-Methods Systematic Review.Healthcare (Basel, Switzerland) · 2026Review
- The impact of pregnancy on mortality and lung function in cystic fibrosis patients.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- Contraceptive use and pregnancy in cystic fibrosis: Survey findings from 10 cystic fibrosis centers.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- The CFTR K464N variant in fetuses potential increases premature birth risk in Chinese families.Human genomics · 2025Article
- Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis.Archives of microbiology · 2024Review
- Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.Archives of gynecology and obstetrics · 2024Review
- Preventable Hazards from in Vitro Fertilization - A Case Series of CF Patients from Bulgaria.Balkan journal of medical genetics : BJMG · 2023Article
- Pregnancy in Cystic Fibrosis-Past, Present, and Future.Journal of clinical medicine · 2023Review
- Ocular development after highly effective modulator treatment early in life.Frontiers in pharmacology · 2023Review
- Maternal, newborn and breast milk concentrations of elexacaftor/tezacaftor/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy.Frontiers in medicine · 2023Article
- Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2022Article
- Management of pregnancy in cystic fibrosis.Breathe (Sheffield, England) · 2022Review
- Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!American journal of respiratory and critical care medicine · 2022Article
- Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis.Pediatric pulmonology · 2022Review
- Family-building and parenting considerations for people with cystic fibrosis.Pediatric pulmonology · 2022Review
- Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor.Respiratory medicine case reports · 2022Article
- The Prognosis of ART Is Not Altered in Cystic Fibrosis Women: A Case-Report Study.Frontiers in endocrinology · 2022Article
- Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy.Breathe (Sheffield, England) · 2021Review
- Gynecologic health care for females with cystic fibrosis.Journal of clinical & translational endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cystic fibrosis (CF) is a life-shortening genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations lead to abnormal ion transport in mucous membranes throughout the body, including in the respiratory and gastrointestinal and reproductive tracts. Improvements in care and therapy have led to substantial increases in the quantity and quality of life for those with CF. Consequently, women with CF are increasingly interested in having families. Although pregnancy was once discouraged for women with CF, at this point, even women with moderately severe lung disease can successfully navigate pregnancy. With the recent approval of a triple combination CFTR modulator therapy that improves lung function, nutritional status, and quality of life for people with a single copy of the most common CFTR mutation, it is expected that the number of women with CF who choose to become pregnant will continue to increase. Although animal reproduction models show no alarming signals for use during pregnancy at normal human doses, there is a paucity of human safety data in pregnancy and lactation. This review summarizes what is currently known about the impact of use of CFTR modulators on fertility, pregnancy, and lactation in women with CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.